Folate Receptor-Mediated Drug Targeting: From Therapeutics to Diagnostics
Folate targeted drug delivery has emerged as an alternative therapy for the treatment and imaging of many cancers and inflammatory diseases. Due to its small molecular size and high binding affinity for cell surface folate receptors (FR), folate conjugates have the ability to deliver a variety of mo...
Gespeichert in:
| Veröffentlicht in: | Journal of pharmaceutical sciences 2005-10, Vol.94 (10), p.2135-2146 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2146 |
|---|---|
| container_issue | 10 |
| container_start_page | 2135 |
| container_title | Journal of pharmaceutical sciences |
| container_volume | 94 |
| creator | Hilgenbrink, Andrew R. Low, Philip S. |
| description | Folate targeted drug delivery has emerged as an alternative therapy for the treatment and imaging of many cancers and inflammatory diseases. Due to its small molecular size and high binding affinity for cell surface folate receptors (FR), folate conjugates have the ability to deliver a variety of molecular complexes to pathologic cells without causing harm to normal tissues. Complexes that have been successfully delivered to FR expressing cells, to date, include protein toxins, immune stimulants, chemotherapeutic agents, liposomes, nanoparticles, and imaging agents. This review will summarize the applications of folic acid as a targeting ligand and highlight the various methods being developed for delivery of therapeutic and imaging agents to FR-expressing cells. © 2005 Wiley-Liss, Inc. and the American Pharmacists Association |
| doi_str_mv | 10.1002/jps.20457 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68555758</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022354916318688</els_id><sourcerecordid>68555758</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5017-9e7dc45f26eee9e0d70d482afd86303fdb6144a04ac48b5b16a429da6bce341e3</originalsourceid><addsrcrecordid>eNp1kV1T1DAUhjOMDqzohX_A6Y3OeFFImq8ud7i4CKJ8uI7cZdLkdA12m5q0Av-eYFe4watMkue85-QJQq8J3iEYF7tXXdwpMONyA00IL3AuMJHP0CTdFTnlbLqFXsR4hTEWmPNNtEUEoYLzcoKO5r7RPWQXYKDrfci_gHXpwGYHYVhmCx2W0Lt2uZfNg19li58QdAdD70zMep8dOL1sfbzfvkTPa91EeLVet9H3-cfF7FN-cnp4NNs_yQ1PU-VTkNYwXhcCAKaArcSWlYWubSkoprWtBGFMY6YNKyteEaFZMbVaVAYoI0C30bsxtwv-9wCxVysXDTSNbsEPUYmScy55mcD3I2iCjzFArbrgVjrcKoLVvTeVvKm_3hL7Zh06VCuwj-RaVALergEdjW7qoFvj4iMniaRU8sTtjty1a-D2_x3V8dm3f63zscLFHm4eKnT4pYRMkerH10MlLz_g88_nF2qWeDrykCT_cRBUNA5ak_4tgOmV9e6JB94B3lCk9Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68555758</pqid></control><display><type>article</type><title>Folate Receptor-Mediated Drug Targeting: From Therapeutics to Diagnostics</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><source>Alma/SFX Local Collection</source><creator>Hilgenbrink, Andrew R. ; Low, Philip S.</creator><creatorcontrib>Hilgenbrink, Andrew R. ; Low, Philip S.</creatorcontrib><description>Folate targeted drug delivery has emerged as an alternative therapy for the treatment and imaging of many cancers and inflammatory diseases. Due to its small molecular size and high binding affinity for cell surface folate receptors (FR), folate conjugates have the ability to deliver a variety of molecular complexes to pathologic cells without causing harm to normal tissues. Complexes that have been successfully delivered to FR expressing cells, to date, include protein toxins, immune stimulants, chemotherapeutic agents, liposomes, nanoparticles, and imaging agents. This review will summarize the applications of folic acid as a targeting ligand and highlight the various methods being developed for delivery of therapeutic and imaging agents to FR-expressing cells. © 2005 Wiley-Liss, Inc. and the American Pharmacists Association</description><identifier>ISSN: 0022-3549</identifier><identifier>EISSN: 1520-6017</identifier><identifier>DOI: 10.1002/jps.20457</identifier><identifier>PMID: 16136558</identifier><identifier>CODEN: JPMSAE</identifier><language>eng</language><publisher>Hoboken: Elsevier Inc</publisher><subject>Animals ; Antineoplastic Agents - administration & dosage ; Antineoplastic Agents - therapeutic use ; arthritis ; Biological and medical sciences ; Biomarkers, Tumor - metabolism ; cancer chemotherapy ; Carrier Proteins - metabolism ; Drug Delivery Systems ; folate conjugate ; folate receptor ; Folate Receptors, GPI-Anchored ; Folic Acid - administration & dosage ; Folic Acid - chemistry ; General pharmacology ; Humans ; imaging methods ; Immunotherapy ; inflammatory disease ; Liposomes ; Medical sciences ; nanoparticles ; Nanostructures ; Neoplasms - diagnostic imaging ; Neoplasms - drug therapy ; Neoplasms - metabolism ; Neoplasms - therapy ; Pharmaceutical technology. Pharmaceutical industry ; Pharmacology. Drug treatments ; Radionuclide Imaging ; Radiopharmaceuticals ; Receptors, Cell Surface - metabolism ; targeted drug delivery ; Toxins, Biological - administration & dosage ; Toxins, Biological - therapeutic use</subject><ispartof>Journal of pharmaceutical sciences, 2005-10, Vol.94 (10), p.2135-2146</ispartof><rights>2005 Wiley-Liss, Inc.</rights><rights>Copyright © 2005 Wiley‐Liss, Inc.</rights><rights>2005 INIST-CNRS</rights><rights>Copyright (c) 2005 Wiley-Liss, Inc. and the American Pharmacists Association</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5017-9e7dc45f26eee9e0d70d482afd86303fdb6144a04ac48b5b16a429da6bce341e3</citedby><cites>FETCH-LOGICAL-c5017-9e7dc45f26eee9e0d70d482afd86303fdb6144a04ac48b5b16a429da6bce341e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjps.20457$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjps.20457$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,782,786,1419,27933,27934,45583,45584</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17173375$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16136558$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hilgenbrink, Andrew R.</creatorcontrib><creatorcontrib>Low, Philip S.</creatorcontrib><title>Folate Receptor-Mediated Drug Targeting: From Therapeutics to Diagnostics</title><title>Journal of pharmaceutical sciences</title><addtitle>J. Pharm. Sci</addtitle><description>Folate targeted drug delivery has emerged as an alternative therapy for the treatment and imaging of many cancers and inflammatory diseases. Due to its small molecular size and high binding affinity for cell surface folate receptors (FR), folate conjugates have the ability to deliver a variety of molecular complexes to pathologic cells without causing harm to normal tissues. Complexes that have been successfully delivered to FR expressing cells, to date, include protein toxins, immune stimulants, chemotherapeutic agents, liposomes, nanoparticles, and imaging agents. This review will summarize the applications of folic acid as a targeting ligand and highlight the various methods being developed for delivery of therapeutic and imaging agents to FR-expressing cells. © 2005 Wiley-Liss, Inc. and the American Pharmacists Association</description><subject>Animals</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>arthritis</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>cancer chemotherapy</subject><subject>Carrier Proteins - metabolism</subject><subject>Drug Delivery Systems</subject><subject>folate conjugate</subject><subject>folate receptor</subject><subject>Folate Receptors, GPI-Anchored</subject><subject>Folic Acid - administration & dosage</subject><subject>Folic Acid - chemistry</subject><subject>General pharmacology</subject><subject>Humans</subject><subject>imaging methods</subject><subject>Immunotherapy</subject><subject>inflammatory disease</subject><subject>Liposomes</subject><subject>Medical sciences</subject><subject>nanoparticles</subject><subject>Nanostructures</subject><subject>Neoplasms - diagnostic imaging</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - metabolism</subject><subject>Neoplasms - therapy</subject><subject>Pharmaceutical technology. Pharmaceutical industry</subject><subject>Pharmacology. Drug treatments</subject><subject>Radionuclide Imaging</subject><subject>Radiopharmaceuticals</subject><subject>Receptors, Cell Surface - metabolism</subject><subject>targeted drug delivery</subject><subject>Toxins, Biological - administration & dosage</subject><subject>Toxins, Biological - therapeutic use</subject><issn>0022-3549</issn><issn>1520-6017</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kV1T1DAUhjOMDqzohX_A6Y3OeFFImq8ud7i4CKJ8uI7cZdLkdA12m5q0Av-eYFe4watMkue85-QJQq8J3iEYF7tXXdwpMONyA00IL3AuMJHP0CTdFTnlbLqFXsR4hTEWmPNNtEUEoYLzcoKO5r7RPWQXYKDrfci_gHXpwGYHYVhmCx2W0Lt2uZfNg19li58QdAdD70zMep8dOL1sfbzfvkTPa91EeLVet9H3-cfF7FN-cnp4NNs_yQ1PU-VTkNYwXhcCAKaArcSWlYWubSkoprWtBGFMY6YNKyteEaFZMbVaVAYoI0C30bsxtwv-9wCxVysXDTSNbsEPUYmScy55mcD3I2iCjzFArbrgVjrcKoLVvTeVvKm_3hL7Zh06VCuwj-RaVALergEdjW7qoFvj4iMniaRU8sTtjty1a-D2_x3V8dm3f63zscLFHm4eKnT4pYRMkerH10MlLz_g88_nF2qWeDrykCT_cRBUNA5ak_4tgOmV9e6JB94B3lCk9Q</recordid><startdate>200510</startdate><enddate>200510</enddate><creator>Hilgenbrink, Andrew R.</creator><creator>Low, Philip S.</creator><general>Elsevier Inc</general><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley</general><general>American Pharmaceutical Association</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200510</creationdate><title>Folate Receptor-Mediated Drug Targeting: From Therapeutics to Diagnostics</title><author>Hilgenbrink, Andrew R. ; Low, Philip S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5017-9e7dc45f26eee9e0d70d482afd86303fdb6144a04ac48b5b16a429da6bce341e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Animals</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>arthritis</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>cancer chemotherapy</topic><topic>Carrier Proteins - metabolism</topic><topic>Drug Delivery Systems</topic><topic>folate conjugate</topic><topic>folate receptor</topic><topic>Folate Receptors, GPI-Anchored</topic><topic>Folic Acid - administration & dosage</topic><topic>Folic Acid - chemistry</topic><topic>General pharmacology</topic><topic>Humans</topic><topic>imaging methods</topic><topic>Immunotherapy</topic><topic>inflammatory disease</topic><topic>Liposomes</topic><topic>Medical sciences</topic><topic>nanoparticles</topic><topic>Nanostructures</topic><topic>Neoplasms - diagnostic imaging</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - metabolism</topic><topic>Neoplasms - therapy</topic><topic>Pharmaceutical technology. Pharmaceutical industry</topic><topic>Pharmacology. Drug treatments</topic><topic>Radionuclide Imaging</topic><topic>Radiopharmaceuticals</topic><topic>Receptors, Cell Surface - metabolism</topic><topic>targeted drug delivery</topic><topic>Toxins, Biological - administration & dosage</topic><topic>Toxins, Biological - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hilgenbrink, Andrew R.</creatorcontrib><creatorcontrib>Low, Philip S.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of pharmaceutical sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hilgenbrink, Andrew R.</au><au>Low, Philip S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Folate Receptor-Mediated Drug Targeting: From Therapeutics to Diagnostics</atitle><jtitle>Journal of pharmaceutical sciences</jtitle><addtitle>J. Pharm. Sci</addtitle><date>2005-10</date><risdate>2005</risdate><volume>94</volume><issue>10</issue><spage>2135</spage><epage>2146</epage><pages>2135-2146</pages><issn>0022-3549</issn><eissn>1520-6017</eissn><coden>JPMSAE</coden><abstract>Folate targeted drug delivery has emerged as an alternative therapy for the treatment and imaging of many cancers and inflammatory diseases. Due to its small molecular size and high binding affinity for cell surface folate receptors (FR), folate conjugates have the ability to deliver a variety of molecular complexes to pathologic cells without causing harm to normal tissues. Complexes that have been successfully delivered to FR expressing cells, to date, include protein toxins, immune stimulants, chemotherapeutic agents, liposomes, nanoparticles, and imaging agents. This review will summarize the applications of folic acid as a targeting ligand and highlight the various methods being developed for delivery of therapeutic and imaging agents to FR-expressing cells. © 2005 Wiley-Liss, Inc. and the American Pharmacists Association</abstract><cop>Hoboken</cop><pub>Elsevier Inc</pub><pmid>16136558</pmid><doi>10.1002/jps.20457</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-3549 |
| ispartof | Journal of pharmaceutical sciences, 2005-10, Vol.94 (10), p.2135-2146 |
| issn | 0022-3549 1520-6017 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68555758 |
| source | MEDLINE; Access via Wiley Online Library; Alma/SFX Local Collection |
| subjects | Animals Antineoplastic Agents - administration & dosage Antineoplastic Agents - therapeutic use arthritis Biological and medical sciences Biomarkers, Tumor - metabolism cancer chemotherapy Carrier Proteins - metabolism Drug Delivery Systems folate conjugate folate receptor Folate Receptors, GPI-Anchored Folic Acid - administration & dosage Folic Acid - chemistry General pharmacology Humans imaging methods Immunotherapy inflammatory disease Liposomes Medical sciences nanoparticles Nanostructures Neoplasms - diagnostic imaging Neoplasms - drug therapy Neoplasms - metabolism Neoplasms - therapy Pharmaceutical technology. Pharmaceutical industry Pharmacology. Drug treatments Radionuclide Imaging Radiopharmaceuticals Receptors, Cell Surface - metabolism targeted drug delivery Toxins, Biological - administration & dosage Toxins, Biological - therapeutic use |
| title | Folate Receptor-Mediated Drug Targeting: From Therapeutics to Diagnostics |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-02T02%3A25%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Folate%20Receptor-Mediated%20Drug%20Targeting:%20From%20Therapeutics%20to%20Diagnostics&rft.jtitle=Journal%20of%20pharmaceutical%20sciences&rft.au=Hilgenbrink,%20Andrew%20R.&rft.date=2005-10&rft.volume=94&rft.issue=10&rft.spage=2135&rft.epage=2146&rft.pages=2135-2146&rft.issn=0022-3549&rft.eissn=1520-6017&rft.coden=JPMSAE&rft_id=info:doi/10.1002/jps.20457&rft_dat=%3Cproquest_cross%3E68555758%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68555758&rft_id=info:pmid/16136558&rft_els_id=S0022354916318688&rfr_iscdi=true |